Soumit Roy, an analyst from JonesTrading, reiterated the Buy rating on OnKure Therapeutics. The associated price target was lowered to $17.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy has given his Buy rating due to a combination of factors surrounding OnKure Therapeutics’ strategic decisions and market positioning. The company has decided to delay the release of key data to the first quarter of 2026 to ensure a comprehensive and meaningful dataset, particularly in the HR+/HER2- breast cancer setting. This move is seen as prudent, allowing investors to make informed decisions based on robust data from their triplet combination therapies.
Additionally, OnKure’s expansion into the PI3KCA-driven vascular malformations space indicates a strategic diversification that could open new market opportunities. With a cash runway extending into the fourth quarter of 2026, the company is positioned to manage its resources effectively while pursuing these promising avenues. The anticipated data release in early 2026 is expected to provide a clearer comparison to competitors like Lilly, potentially positioning OnKure favorably in the oncology landscape.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $21.00 price target.